Soterix Medical Inc. of New York, NY at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

Soterix Medical Inc.

237 West 35th Street, 1401, 10001 New York, NY
USA
Telephone +1 917 8099260
Fax +1 212 3153232
contact@soterixmedical.com

Hall map

MEDICA 2018 hall map (Hall 11): stand A11

Fairground map

MEDICA 2018 fairground map: Hall 11

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.11  Other equipment for electromedicine / medical technology

Other equipment for electromedicine / medical technology

Our products

Product category: Other equipment for electromedicine / medical technology

Neurotargeting Software

Optimize current delivery to targeted brain regions.
Optimization of electrode montage for brain targeting and individual subject customization has never been as easy as with Soterix Medical's Neurotargeting software. With recognition that placing an electrode "over" a target does not support rational tDCS dose design, the Soterix Medical suite of software tools allow simple and automatic optimization. Optimized dose can then be used to configure your Soterix tDCS and HD-tDCS stimulator. Soterix Neurotargeting software also provides high-resolution current flow visualization that can be used to support publications, presentations and proposals.

What is Neurotargeting?
Neurotargeting is not neuronavigation. Neuronavigation assists in the placing of electrodes or coils "over" brain regions. Neurotargeting automatically pre-determines the optimal electrode placement based on clinician identified brain targets and subject specific anatomy. The electrode montage (based on EEG 10/10) parameters can then be programmed into Soterix Medical stimulators to achieve optimal brain current flow. Soterix Medical image processing captures true 1 mm anatomical resolution and cortical folding while custom current-flow optimization provides the precise best configuration. Neurotargeting yields a true optimized stimulation montage and the high-resolution current flow visualization to prove it.

Additional Resources

Optimized multi-electrode stimulation increases focality and intensity at target.
Dmochowski JP, Datta A, Bikson M, Su Y, Parra LC

More Less

About us

Company details

Overview
Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 250 medical centers in the US and worldwide. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. Ongoing Phase I, II, IIb, and III trials use investigational devices that are regulated/limited by US or Federal law. SMI is proudly based in New York City with international distributors in all major markets.

Engineering Serving Humanity: At Soterix Medical, Engineering Serving Humanity means that we are committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.

tDCS-Limited Total Energy (LTE™) is an exclusive neuromodulation technology developed by Soterix Medical Inc. Invented at The City College of New York, tDCS-LTE is the only tDCS technology platform optimized for robust low-energy Transcranial Direct Current Stimulation. tDCS-LTE is under investigation in susceptible populations including stroke, pediatric, traumatic brain injury, etc. tDCS-LTE is made possible through a proprietary adaptive stimulation limiting the voltage and power required for tDCS. Soterix Medical tDCS-LTE is the only non-invasive neuromodulation technology further optimized for robust deployment in a wide variety of environments including emergency medicine, field-work, home-use, etc.

High Definition tDCS (HD-tDCS) is an exclusive Neuromodulation technology developed by Soterix Medical Inc. Invented at The City College of New York, it is the only technology platform that allows tolerated non-invasive delivery of therapeutic current to desired brain regions. As a result, HD-tDCS offers potential for safe and effective treatment of neuropsychiatric disorders not possible with any other technology. HD-tDCS is made possible through innovations in electrode design allowing safe and tolerated passage of current through proprietary “High-Definition” electrodes, individualized brain current-flow modeling and through patented targeting algorithms indicating how to place and energize HD-electrodes on the head.

CAUTION: Investigational device. Limited by Federal (or US) law to investigational use.

More Less